Cardiovascular Considerations After Cancer Therapy: Gaps in Evidence and Expert Panel Recommendations

Overview

Journal JACC CardioOncol

Date 2025 Feb 3

PMID 39896126

Authors

Anne Blaes

Anju Nohria

Saro Armenian

Carmen Bergom

Paaladinesh Thavendiranathan

Ana Barac

Gabriela Sanchez-Petitto

Sanjal Desai

Leah L Zullig

Alicia K Morgans

Joerg Herrmann

Affiliations

Soon will be listed here.

Abstract

Cancer survivors, particularly those treated with anthracyclines and chest radiation, face an elevated risk of cancer therapy-related cardiovascular toxicity. These complications affect not only physical health, but also life expectancy. Risk factors for cancer therapy-related cardiovascular toxicity include age at which cancer treatment was received, the use of (potentially) cardiotoxic cancer therapies, and the presence of concomitant cardiovascular risk factors. Current guidelines provide recommendations for cardiovascular surveillance after cancer therapy, including type and frequency. All cancer survivors are advised to undergo annual clinical screenings and optimization of cardiovascular risk factors. Those at higher risk should undergo additional cardiovascular testing. This document aims to summarize the available evidence, present practical recommendations, and outline existent gaps in the current literature regarding cardiovascular care after cancer therapies.

References

Bergom C, Bradley J, Ng A, Samson P, Robinson C, Lopez-Mattei J . Past, Present, and Future of Radiation-Induced Cardiotoxicity: Refinements in Targeting, Surveillance, and Risk Stratification. JACC CardioOncol. 2021; 3(3):343-359. PMC: 8463722. DOI: 10.1016/j.jaccao.2021.06.007. View

Ehrhardt M, Ward Z, Liu Q, Chaudhry A, Nohria A, Border W . Cost-Effectiveness of the International Late Effects of Childhood Cancer Guideline Harmonization Group Screening Guidelines to Prevent Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2020; 38(33):3851-3862. PMC: 7676889. DOI: 10.1200/JCO.20.00418. View

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

Nguyen P, Je Y, Schutz F, Hoffman K, Hu J, Parekh A . Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA. 2011; 306(21):2359-66. DOI: 10.1001/jama.2011.1745. View

Atkins K, Chaunzwa T, Lamba N, Bitterman D, Rawal B, Bredfeldt J . Association of Left Anterior Descending Coronary Artery Radiation Dose With Major Adverse Cardiac Events and Mortality in Patients With Non-Small Cell Lung Cancer. JAMA Oncol. 2020; 7(2):206-219. PMC: 7747040. DOI: 10.1001/jamaoncol.2020.6332. View

Fleming M, Xiao L, Jackson K, Beckman J, Barac A, Moslehi J . Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors. Circ Res. 2021; 128(12):1973-1987. PMC: 10185355. DOI: 10.1161/CIRCRESAHA.121.318259. View

Armenian S, Xu L, Ky B, Sun C, Farol L, Pal S . Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016; 34(10):1122-30. PMC: 7357493. DOI: 10.1200/JCO.2015.64.0409. View

Dhopeshwarkar N, Iqbal S, Wang X, Salas M . A Retrospective Study of Comorbidities and Complications in Elderly Acute Myeloid Leukemia Patients in the United States. Clin Lymphoma Myeloma Leuk. 2019; 19(8):e436-e456. DOI: 10.1016/j.clml.2019.04.012. View

Bhatia S, Francisco L, Carter A, Sun C, Baker K, Gurney J . Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007; 110(10):3784-92. PMC: 2077324. DOI: 10.1182/blood-2007-03-082933. View

10.

Awan F, Addison D, Alfraih F, Baratta S, Campos R, Cugliari M . International consensus statement on the management of cardiovascular risk of Bruton's tyrosine kinase inhibitors in CLL. Blood Adv. 2022; 6(18):5516-5525. PMC: 9631706. DOI: 10.1182/bloodadvances.2022007938. View

11.

Chow E, Chen Y, Hudson M, Feijen E, Kremer L, Border W . Prediction of Ischemic Heart Disease and Stroke in Survivors of Childhood Cancer. J Clin Oncol. 2017; 36(1):44-52. PMC: 5756324. DOI: 10.1200/JCO.2017.74.8673. View

12.

Chen Y, Chow E, Oeffinger K, Border W, Leisenring W, Meacham L . Traditional Cardiovascular Risk Factors and Individual Prediction of Cardiovascular Events in Childhood Cancer Survivors. J Natl Cancer Inst. 2019; 112(3):256-265. PMC: 7073918. DOI: 10.1093/jnci/djz108. View

13.

Zullig L, Drake C, Shahsahebi M, Avecilla R, Whitney C, Mills C . Adherence to cardiovascular disease risk factor medications among patients with cancer: a systematic review. J Cancer Surviv. 2022; 17(3):595-618. PMC: 9923500. DOI: 10.1007/s11764-022-01212-0. View

14.

Halliday B, Wassall R, Lota A, Khalique Z, Gregson J, Newsome S . Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2018; 393(10166):61-73. PMC: 6319251. DOI: 10.1016/S0140-6736(18)32484-X. View

15.

Leiva O, Hobbs G, Ravid K, Libby P . Cardiovascular Disease in Myeloproliferative Neoplasms: State-of-the-Art Review. JACC CardioOncol. 2022; 4(2):166-182. PMC: 9270630. DOI: 10.1016/j.jaccao.2022.04.002. View

16.

van Nimwegen F, Ntentas G, Darby S, Schaapveld M, Hauptmann M, Lugtenburg P . Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017; 129(16):2257-2265. PMC: 5418626. DOI: 10.1182/blood-2016-09-740332. View

17.

Copelan E . Hematopoietic stem-cell transplantation. N Engl J Med. 2006; 354(17):1813-26. DOI: 10.1056/NEJMra052638. View

18.

Wingard J, Majhail N, Brazauskas R, Wang Z, Sobocinski K, Jacobsohn D . Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011; 29(16):2230-9. PMC: 3107742. DOI: 10.1200/JCO.2010.33.7212. View

19.

Pagani O, Walley B, Fleming G, Colleoni M, Lang I, Gomez H . Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2022; 41(7):1376-1382. PMC: 10419413. DOI: 10.1200/JCO.22.01064. View

20.

Lauritsen J, Hansen M, Bandak M, Kreiberg M, Skott J, Wagner T . Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer. J Clin Oncol. 2019; 38(6):584-592. DOI: 10.1200/JCO.19.01180. View